We are a clinical-stage biotechnology company committed to bringing safe, effective, and potentially curative antibody-drug conjugate (ADC) therapies to cancer patients worldwide. Guided by a deep understanding of cancer biology and clinical needs, we pursue a differentiated drug development strategy centered on the discovery and development of ADCs with novel mechanisms of action for the treatment of solid tumors with significant unmet medical needs, including epidermal growth factor receptor (EGFR) wild-type non-squamous non-small cell lung cancer (NSCLC), melanoma, gastrointestinal cancers (such as colorectal cancer (CRC)), and gynecological cancers.

Company Milestones